In patients with head and neck cancer undergoing radiotherapy, applying radiation very close to the mouth can destroy some salivary glands and compromise saliva production, which is essential for controlling bacteria and disease

BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment

Glutamine silences BATF2 and leads to a weakened immune response

Blocking glutamine reverses these effects, increasing BATF2 expression and improving overall immunity

Researchers used a panel to assess the presence of circulating tumor DNA in plasma samples and detected changes in genes related to the development of adenocarcinoma that indicated both actionability by drugs and resistance to treatment.

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy, according to a new study led by Weill Cornell Medicine and Cornell Engineering researchers.

Adolescent and young adult cancer survivors age faster than their peers who did not have cancer, according to a new study, which also describes how accelerated aging occurs both at the cellular level and in brain function, such as memory, attention, and ability to process information.

A large national and international study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups. Published in Nature Communications, the study seeks to improve understanding the various causes of prostate cancer across different populations. The study is led by Dr. Lang Wu, Associate Director of Population Science - LSU LCMC Health Cancer Center, highlighting Louisiana’s growing role as a national leader in cutting-edge cancer research. The study can be viewed here: https://www.nature.com/articles/s41467-025-66250-5.

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.